Read Deb’s story
Deb is raising money to help Myeloma UK
Related Articles
Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era – PubMed
Multiple myeloma (MM) derives from the clonal proliferation of plasma cells, primarily residing in the bone marrow. However, MM cells can disseminate systemically, leading to…
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma – PubMed
BackgroundMultiple myeloma (MM) is virtually always preceded by monoclonal gammopathy of undetermined significance (MGUS). Elevated serum markers are used to classify MGUS patients into clinical…
Myeloma Paper of the Day, June 21st, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, June 21st, suggested by Robert Orlowski / cancer, Emiko Sakaida, Kazumoto Shibuya, Marie Morooka, MM, Moeko Ogushi, Myeloma, Myeloma
Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series – PubMed
Daratumumab- and elotuzumab-based regimens may be treatment options for refractory POEMS syndrome.
Declan’s fundraiser for PROSTATE CANCER UK
Help Declan Cahill raise money to support PROSTATE CANCER UK
Team fundraising for Sussex Cancer Fund & RNLI
Help Joanna Stokoe raise money to support Sussex Cancer Fund
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post-hoc analysis of BENEFIT – PubMed
In summary, the cumulative incidence of VTE remains high in patients with TI nMM. DOACs could be the most effective option for preventing VTE.